National Institute for Health and Care Excellence22d
Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer
There is a commercial access agreement for durvalumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
BBC22d
Experts hail bladder cancer drug 'breakthrough'
University of Sheffield experts said the drug durvalumab could reduce the recurrence of operable bladder cancer by a third Medical experts in Sheffield have hailed as a "game changer" trials of a ...
The Independent24d
‘Increased survival rates’ for bladder cancer patients given immunotherapy drug
Patients with advanced (muscle-invasive) bladder cancer had significantly less risk of cancer progressing or returning when treated with durvalumab, and were more likely to still be alive two ...
The Independent24d
‘Game changer’ immunotherapy drug could lead to increased survival rates for bladder cancer patients
The study found that patients with muscle-invasive bladder cancer had significantly less risk of cancer progressing or returning when treated with immunosurpressant drug durvalumab, and were more ...
National Institute for Health and Care Excellence22d
Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer
Durvalumab is recommended, within its marketing authorisation, as neoadjuvant treatment with platinum-based chemotherapy, then continued alone as adjuvant treatment, for treating non-small-cell lung ...
BBC22d
Experts hail bladder cancer drug 'breakthrough'
Using the immunotherapy drug durvalumab before and after surgery reduced the recurrence of operable bladder cancer by a third, the trial found. Overall survival rates among patients treated with ...